CRISPR THERAPEUTICS AG Increase (Decrease) in Contract with Customer, Liability
CRISPR THERAPEUTICS AG (CRSP) reported Increase (Decrease) in Contract with Customer, Liability of -$582.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-03
- CRISPR THERAPEUTICS AG increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$155.00K.
- CRISPR THERAPEUTICS AG increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$427.00K.
- CRISPR THERAPEUTICS AG increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was $2.15M.
- CRISPR THERAPEUTICS AG increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$834.00K.
- CRISPR THERAPEUTICS AG increase (decrease) in contract with customer, liability for fiscal 2025 was -$397.00K.
- CRISPR THERAPEUTICS AG increase (decrease) in contract with customer, liability for fiscal 2024 was -$1.95M, a 133.64% decline from fiscal 2023.
- CRISPR THERAPEUTICS AG increase (decrease) in contract with customer, liability for fiscal 2023 was $5.79M.
- CRISPR THERAPEUTICS AG increase (decrease) in contract with customer, liability for fiscal 2022 was -$1.01M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$155.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$582.00K 10-Q · filed 2026-08-03 | $1.57M derived: sum of 3 quarters · filed 2026-08-03 | $737.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$427.00K 10-Q · filed 2026-05-04 | $1.73M derived: sum of 2 quarters · filed 2026-05-04 | $892.00K derived: sum of 3 quarters · filed 2026-05-04 | $0.00 derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $1.32M derived: sum of 2 quarters · filed 2026-02-12 | $427.00K derived: sum of 3 quarters · filed 2026-08-03 | -$397.00K 10-K · filed 2026-02-12 |
| 2025-09-30 | -$834.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$1.73M derived: sum of 2 quarters · filed 2026-08-03 | -$2.55M 10-Q · filed 2025-11-10 | -$3.19M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$892.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$1.72M 10-Q · filed 2026-08-03 | -$2.35M derived: sum of 3 quarters · filed 2026-08-03 | -$2.89M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$824.00K 10-Q · filed 2026-05-04 | -$1.46M derived: sum of 2 quarters · filed 2026-05-04 | -$2.00M derived: sum of 3 quarters · filed 2026-05-04 | -$2.27M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$638.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$1.17M derived: sum of 2 quarters · filed 2026-02-12 | -$1.45M derived: sum of 3 quarters · filed 2026-02-12 | -$1.95M 10-K · filed 2026-02-12 |
| 2024-09-30 | -$536.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$807.00K derived: sum of 2 quarters · filed 2025-11-10 | -$1.31M 10-Q · filed 2025-11-10 | -$2.52M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | -$271.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | -$775.00K 10-Q · filed 2025-08-04 | -$1.98M derived: sum of 3 quarters · filed 2026-02-12 | $5.02M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | -$504.00K 10-Q · filed 2025-05-06 | -$1.71M derived: sum of 2 quarters · filed 2026-02-12 | $5.29M derived: sum of 3 quarters · filed 2026-02-12 | $5.29M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | -$1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $5.79M derived: sum of 2 quarters · filed 2026-02-12 | $5.79M derived: sum of 3 quarters · filed 2026-02-12 | $5.79M 10-K · filed 2026-02-12 |
| 2023-09-30 | $7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $7.00M derived: sum of 2 quarters · filed 2024-11-05 | $7.00M 10-Q · filed 2024-11-05 | $6.75M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $0.00 10-Q · filed 2024-08-05 | -$249.00K derived: sum of 3 quarters · filed 2025-02-11 | $0.00 derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | -$249.00K derived: sum of 2 quarters · filed 2025-02-11 | $0.00 derived: sum of 3 quarters · filed 2025-02-11 | -$249.00K derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | -$249.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $0.00 derived: sum of 2 quarters · filed 2025-02-11 | -$249.00K derived: sum of 3 quarters · filed 2025-02-11 | -$1.01M 10-K · filed 2025-02-11 |
| 2022-09-30 | $249.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $0.00 derived: sum of 2 quarters · filed 2023-11-06 | -$762.00K 10-Q · filed 2023-11-06 | -$766.00K derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | -$249.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$1.01M 10-Q · filed 2023-08-07 | -$1.01M derived: sum of 3 quarters · filed 2024-02-21 | -$1.52M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | -$762.00K 10-Q · filed 2022-05-09 | -$766.00K derived: sum of 2 quarters · filed 2024-02-21 | -$1.27M derived: sum of 3 quarters · filed 2024-02-21 | -$1.01M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | -$512.00K derived: sum of 2 quarters · filed 2024-02-21 | -$244.00K derived: sum of 3 quarters · filed 2024-02-21 | -$783.00K 10-K · filed 2024-02-21 |
| 2021-09-30 | -$508.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | -$240.00K derived: sum of 2 quarters · filed 2022-11-01 | -$779.00K 10-Q · filed 2022-11-01 | $952.00K derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $268.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$271.00K 10-Q · filed 2022-08-08 | $1.46M derived: sum of 3 quarters · filed 2023-02-21 | $1.31M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | -$539.00K 10-Q · filed 2022-05-09 | $1.19M derived: sum of 2 quarters · filed 2023-02-21 | $1.04M derived: sum of 3 quarters · filed 2023-02-21 | $999.00K derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $1.58M derived: sum of 2 quarters · filed 2023-02-21 | $1.54M derived: sum of 3 quarters · filed 2023-02-21 | $1.38M 10-K · filed 2023-02-21 |
| 2020-09-30 | -$149.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$193.00K derived: sum of 2 quarters · filed 2021-11-03 | -$350.00K 10-Q · filed 2021-11-03 | -$47.21M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | -$44.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | -$201.00K 10-Q · filed 2021-07-29 | -$47.06M derived: sum of 3 quarters · filed 2022-02-15 | -$45.30M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | -$157.00K 10-Q · filed 2021-04-27 | -$47.02M derived: sum of 2 quarters · filed 2022-02-15 | -$45.25M derived: sum of 3 quarters · filed 2022-02-15 | -$45.28M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | -$46.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | -$45.10M derived: sum of 2 quarters · filed 2022-02-15 | -$45.12M derived: sum of 3 quarters · filed 2022-02-15 | -$45.15M 10-K · filed 2022-02-15 |
| 2019-09-30 | $1.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $1.74M derived: sum of 2 quarters · filed 2020-10-28 | $1.71M 10-Q · filed 2020-10-28 | $1.69M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-06-30 | -$25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-27 | -$50.00K 10-Q · filed 2020-07-27 | -$76.00K derived: sum of 3 quarters · filed 2021-02-16 | -$102.00K derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-03-31 | -$25.00K 10-Q · filed 2020-04-28 | -$51.00K derived: sum of 2 quarters · filed 2021-02-16 | -$77.00K derived: sum of 3 quarters · filed 2021-02-16 | -$103.00K derived: sum of 4 quarters · filed 2021-02-16 |
| 2018-12-31 | -$26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | -$52.00K derived: sum of 2 quarters · filed 2021-02-16 | -$78.00K derived: sum of 3 quarters · filed 2021-02-16 | -$296.00K 10-K · filed 2021-02-16 |
| 2018-09-30 | -$26.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-28 | -$52.00K derived: sum of 2 quarters · filed 2019-10-28 | -$270.00K 10-Q · filed 2019-10-28 | -$23.03M derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-06-30 | -$26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29 | -$244.00K 10-Q · filed 2019-07-29 | -$23.00M derived: sum of 3 quarters · filed 2020-02-12 | |
| 2018-03-31 | -$218.00K 10-Q · filed 2019-04-29 | -$22.98M derived: sum of 2 quarters · filed 2020-02-12 | ||
| 2017-12-31 | -$22.76M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | -$20.72M 10-K · filed 2020-02-12 | ||
| 2017-09-30 | $2.04M 10-Q · filed 2018-11-07 | |||
| 2016-12-31 | $1.92M 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |